JP2022191383A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2022191383A5 JP2022191383A5 JP2022164041A JP2022164041A JP2022191383A5 JP 2022191383 A5 JP2022191383 A5 JP 2022191383A5 JP 2022164041 A JP2022164041 A JP 2022164041A JP 2022164041 A JP2022164041 A JP 2022164041A JP 2022191383 A5 JP2022191383 A5 JP 2022191383A5
- Authority
- JP
- Japan
- Prior art keywords
- antigen
- binding fragment
- seq
- nos
- monoclonal antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000000427 antigen Substances 0.000 claims 11
- 102000036639 antigens Human genes 0.000 claims 11
- 108091007433 antigens Proteins 0.000 claims 11
- 239000012634 fragment Substances 0.000 claims 11
- 102100040243 Microtubule-associated protein tau Human genes 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 8
- 108090000765 processed proteins & peptides Proteins 0.000 claims 8
- 102000004196 processed proteins & peptides Human genes 0.000 claims 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000008194 pharmaceutical composition Substances 0.000 claims 5
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 208000024827 Alzheimer disease Diseases 0.000 claims 2
- 108010047041 Complementarity Determining Regions Proteins 0.000 claims 2
- 238000004220 aggregation Methods 0.000 claims 2
- 230000002776 aggregation Effects 0.000 claims 2
- 230000001575 pathological effect Effects 0.000 claims 2
- 201000011240 Frontotemporal dementia Diseases 0.000 claims 1
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 102000013463 Immunoglobulin Light Chains Human genes 0.000 claims 1
- 108010065825 Immunoglobulin Light Chains Proteins 0.000 claims 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 claims 1
- 239000006143 cell culture medium Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 201000002212 progressive supranuclear palsy Diseases 0.000 claims 1
- 238000003892 spreading Methods 0.000 claims 1
Claims (13)
- （ａ）それぞれ配列番号：７、８、及び９のポリペプチド配列を有する免疫グロブリン重鎖相補性決定領域（ＨＣＤＲ）ＨＣＤＲ１、ＨＣＤＲ２、及びＨＣＤＲ３、並びに、それぞれ配列番号：１９、２０、及び２１のポリペプチド配列を有する免疫グロブリン軽鎖相補性決定領域（ＬＣＤＲ）ＬＣＤＲ１、ＬＣＤＲ２、及びＬＣＤＲ３；又は
（ｂ）それぞれ配列番号：１、２、及び３のポリペプチド配列を有するＨＣＤＲ１、ＨＣＤＲ２、及びＨＣＤＲ３、並びに、それぞれ配列番号：１３、１４、及び１５のポリペプチド配列を有するＬＣＤＲ１、ＬＣＤＲ２、及びＬＣＤＲ３；
を含む、単離モノクローナル抗体又は抗原結合断片であって、ＰＨＦ－タウに結合する、前記単離モノクローナル抗体又は抗原結合断片。 - それぞれ配列番号：７、８、及び９のポリペプチド配列を有するＨＣＤＲ１、ＨＣＤＲ２、及びＨＣＤＲ３、並びに、それぞれ配列番号：１９、２０、及び２１のポリペプチド配列を有するＬＣＤＲ１、ＬＣＤＲ２、及びＬＣＤＲ３を含む、請求項１に記載の単離モノクローナル抗体又は抗原結合断片。
- それぞれ配列番号：１、２、及び３のポリペプチド配列を有するＨＣＤＲ１、ＨＣＤＲ２、及びＨＣＤＲ３、並びに、それぞれ配列番号：１３、１４、及び１５のポリペプチド配列を有するＬＣＤＲ１、ＬＣＤＲ２、及びＬＣＤＲ３を含む、請求項１に記載の単離モノクローナル抗体又は抗原結合断片。
- 配列番号：４５の重鎖、及び配列番号：４６の軽鎖を含む、請求項１に記載の単離モノクローナル抗体又は抗原結合断片。
- 請求項１に記載のモノクローナル抗体又は抗原結合断片をコードする、単離核酸。
- 請求項５に記載の単離核酸を含む、ベクター。
- 請求項５に記載の核酸を含む、宿主細胞。
- 請求項１に記載の単離モノクローナル抗体又は抗原結合断片、及び医薬上許容できる担体を含む、医薬組成物。
- 病理学的タウ凝集の低減、又はタウ異常症の拡大の低減を必要とする対象における、病理学的タウ凝集の低減、又はタウ異常症の拡大の低減のために用いられる、請求項８に記載の医薬組成物。
- タウ異常症の治療を必要とする対象における、タウ異常症の治療のために用いられる、請求項８に記載の医薬組成物。
- 前記タウ異常症は、アルツハイマー病、前頭側頭型認知症、及び進行性核上性麻痺からなる群から選択される、請求項１０に記載の医薬組成物。
- 前記タウ異常症は、アルツハイマー病である、請求項１１に記載の医薬組成物。
- 前記抗体又は抗原結合断片を製造する条件下において、前記抗体又は抗原結合断片をコードする核酸を含む細胞を培養することと、前記細胞又は細胞培養液から前記抗体又は抗原結合断片を回収することとを含む、請求項１に記載のモノクローナル抗体又は抗原結合断片の製造方法。
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762472214P | 2017-03-16 | 2017-03-16 | |
| US62/472,214 | 2017-03-16 | ||
| PCT/US2018/022782 WO2018170351A1 (en) | 2017-03-16 | 2018-03-16 | Anti-phf-tau antibodies and uses thereof |
| JP2019549574A JP7159185B2 (ja) | 2017-03-16 | 2018-03-16 | 抗ｐｈｆ－タウ抗体及びその使用 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549574A Division JP7159185B2 (ja) | 2017-03-16 | 2018-03-16 | 抗ｐｈｆ－タウ抗体及びその使用 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024055230A Division JP2024088689A (ja) | 2017-03-16 | 2024-03-29 | 抗ｐｈｆ－タウ抗体及びその使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2022191383A JP2022191383A (ja) | 2022-12-27 |
| JP2022191383A5 true JP2022191383A5 (ja) | 2023-06-01 |
Family
ID=63521020
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549574A Active JP7159185B2 (ja) | 2017-03-16 | 2018-03-16 | 抗ｐｈｆ－タウ抗体及びその使用 |
| JP2022164041A Withdrawn JP2022191383A (ja) | 2017-03-16 | 2022-10-12 | 抗ｐｈｆ－タウ抗体及びその使用 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019549574A Active JP7159185B2 (ja) | 2017-03-16 | 2018-03-16 | 抗ｐｈｆ－タウ抗体及びその使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (3) | US10766953B2 (ja) |
| EP (1) | EP3596119A4 (ja) |
| JP (2) | JP7159185B2 (ja) |
| KR (2) | KR20230155025A (ja) |
| CN (2) | CN110799531B (ja) |
| AR (1) | AR111288A1 (ja) |
| AU (1) | AU2018234709A1 (ja) |
| BR (3) | BR122023021958A2 (ja) |
| CA (1) | CA3055598A1 (ja) |
| CL (1) | CL2019002566A1 (ja) |
| EA (1) | EA201992038A1 (ja) |
| IL (2) | IL310464A (ja) |
| JO (1) | JOP20180021A1 (ja) |
| MA (1) | MA47789A (ja) |
| MX (1) | MX2019010922A (ja) |
| PH (1) | PH12019501973A1 (ja) |
| SG (1) | SG11201907754RA (ja) |
| TW (1) | TWI771389B (ja) |
| UY (1) | UY37635A (ja) |
| WO (1) | WO2018170351A1 (ja) |
| ZA (1) | ZA202101318B (ja) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6674888B2 (ja) | 2013-03-13 | 2020-04-01 | プロセナ バイオサイエンシーズ リミテッド | タウ免疫療法 |
| FI3452507T3 (fi) | 2016-05-02 | 2022-12-15 | Tau-immuunihoito | |
| EA201892417A1 (ru) | 2016-05-02 | 2019-05-31 | Протена Биосайенсис Лимитед | Антитела, распознающие тау |
| WO2018152359A1 (en) | 2017-02-17 | 2018-08-23 | Denali Therapeutics Inc. | Anti-tau antibodies and methods of use thereof |
| CN110881274A (zh) | 2017-05-02 | 2020-03-13 | 普罗塞纳生物科学有限公司 | 识别tau的抗体 |
| JP6851549B2 (ja) | 2017-10-16 | 2021-03-31 | エーザイ・アール・アンド・ディー・マネジメント株式会社 | 抗タウ抗体及びその使用 |
| BR112021016947A2 (pt) | 2019-03-03 | 2021-11-03 | Prothena Biosciences Ltd | Anticorpos que reconhecem tau |
| CA3140201A1 (en) * | 2019-05-31 | 2020-12-03 | Xiyun CHAI | Compounds and methods targeting human tau |
| CA3148740A1 (en) * | 2019-08-06 | 2021-02-11 | Aprinoia Therapeutics Limited | Antibodies that bind to pathological tau species and uses thereof |
| CR20220505A (es) * | 2020-04-08 | 2023-05-31 | Janssen Biotech Inc | Anticuerpos anti-phf-tau y usos de estos |
| WO2022013286A1 (en) * | 2020-07-14 | 2022-01-20 | Janssen Pharmaceutica Nv | Blood-based assay for detecting tauopathy or amyloidogenic disease |
| CA3199806A1 (en) * | 2020-10-26 | 2022-05-05 | Janssen Pharmaceutica Nv | Methods of reducing tau in human subjects |
| TW202231661A (zh) * | 2020-10-26 | 2022-08-16 | 比利時商健生藥品公司 | 安全投予抗ｔａｕ抗體之方法 |
| AU2022222134A1 (en) * | 2021-02-19 | 2023-07-13 | Eisai R&D Management Co., Ltd. | Anti-pt217 tau antibody |
| WO2022201123A1 (en) | 2021-03-26 | 2022-09-29 | Janssen Biotech, Inc. | Anti-tau antibodies and uses thereof |
| WO2023092004A1 (en) | 2021-11-17 | 2023-05-25 | Voyager Therapeutics, Inc. | Compositions and methods for the treatment of tau-related disorders |
| CN117003863A (zh) * | 2022-04-28 | 2023-11-07 | 厦门大学 | 针对p-tau 217的抗体及其用途 |
| CN116948024B (zh) * | 2023-09-14 | 2024-02-06 | 北京凯祥弘康生物科技有限公司 | 抗Tau蛋白的捕获抗体 |
| CN116948023B (zh) * | 2023-09-14 | 2024-02-09 | 北京凯祥弘康生物科技有限公司 | Tau蛋白抗体及其应用 |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| IL162181A (en) | 1988-12-28 | 2006-04-10 | Pdl Biopharma Inc | A method of producing humanized immunoglubulin, and polynucleotides encoding the same |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| EP1400536A1 (en) | 1991-06-14 | 2004-03-24 | Genentech Inc. | Method for making humanized antibodies |
| JP3909084B2 (ja) | 1991-10-25 | 2007-04-25 | エヌ・ブイ・インノジェネティクス・ソシエテ・アノニム | 微小管結合タンパク質タウに対するモノクローナル抗体 |
| ATE335007T1 (de) * | 1993-12-21 | 2006-08-15 | Innogenetics Nv | Monoklonale antikörper gegen phf-tau, hybridomen die diese ausscheiden, antigenerkennung durch diesen antikörper und deren verwendungen |
| WO1996004309A1 (en) | 1994-07-29 | 1996-02-15 | Innogenetics N.V. | Monoclonal antibodies specific for an epitope of a particular subclass or form of phosphorylated tau, hybridomas secreting them, antigen recognition of these antibodies and their applications |
| EP1539233B1 (en) | 2001-07-12 | 2011-04-27 | FOOTE, Jefferson | Super humanized antibodies |
| WO2004067568A2 (en) | 2003-01-24 | 2004-08-12 | Applied Molecular Evolution, Inc | Human il-1 beta antagonists |
| CA2548817A1 (en) | 2003-12-04 | 2005-06-23 | Xencor, Inc. | Methods of generating variant proteins with increased host string content and compositions thereof |
| EP1720908A2 (en) * | 2004-02-17 | 2006-11-15 | Absalus, Inc. | Super-humanized antibodies against respiratory syncytial virus |
| US20070048785A1 (en) | 2004-06-09 | 2007-03-01 | Lin Laura L | Anti-IL-13 antibodies and complexes |
| EP1790664A1 (en) | 2005-11-24 | 2007-05-30 | Ganymed Pharmaceuticals AG | Monoclonal antibodies against claudin-18 for treatment of cancer |
| ES2452067T3 (es) | 2006-08-04 | 2014-03-31 | Novartis Ag | Anticuerpo específico para EPHB3 y usos del mismo |
| JP2010235447A (ja) | 2007-07-30 | 2010-10-21 | Igaku Seibutsugaku Kenkyusho:Kk | 炎症性サイトカインの抑制剤 |
| EP2347038A4 (en) | 2008-10-14 | 2013-06-12 | Janssen Biotech Inc | METHOD FOR HUMANIZATION AND AFFINITY TREATMENT OF ANTIBODIES |
| DK2356270T3 (da) * | 2008-11-07 | 2016-12-12 | Fabrus Llc | Kombinatoriske antistofbiblioteker og anvendelser deraf |
| US9968574B2 (en) | 2009-05-15 | 2018-05-15 | The University Of Kentucky Research Foundation | Treatment of MCI and Alzheimer's disease |
| US8609097B2 (en) | 2009-06-10 | 2013-12-17 | Hoffmann-La Roche Inc. | Use of an anti-Tau pS422 antibody for the treatment of brain diseases |
| CN106390107B (zh) | 2009-06-10 | 2019-12-31 | 纽约大学 | 病理tau蛋白的免疫靶向 |
| US8912355B2 (en) | 2009-09-29 | 2014-12-16 | University Of Ottawa Heart Institute | Linoleic phospholipids and uses thereof for inhibiting inflammatory and neurodegenerative processes |
| JP2013508287A (ja) | 2009-10-14 | 2013-03-07 | ヤンセン バイオテツク，インコーポレーテツド | 抗体を親和性成熟する方法 |
| ES2566602T3 (es) | 2010-04-09 | 2016-04-14 | Aveo Pharmaceuticals, Inc. | Anticuerpos anti-ErbB3 |
| MY164376A (en) | 2010-10-07 | 2017-12-15 | Univ Leuven Kath | Phosphospecific antibodies recognizing tau |
| EA031698B1 (ru) * | 2010-10-11 | 2019-02-28 | Байоджен Интернэшнл Нейросайенз Гмбх | Человеческие анти-тау антитела |
| AU2012359039B2 (en) | 2011-12-20 | 2017-08-24 | Janssen Biotech, Inc. | Anti-PHF-tau antibodies and their uses |
-
2017
- 2017-03-16 JO JOP/2018/0021A patent/JOP20180021A1/ar unknown
-
2018
- 2018-03-15 TW TW107108890A patent/TWI771389B/zh active
- 2018-03-16 EP EP18767083.1A patent/EP3596119A4/en active Pending
- 2018-03-16 AR ARP180100620A patent/AR111288A1/es unknown
- 2018-03-16 BR BR122023021958-9A patent/BR122023021958A2/pt unknown
- 2018-03-16 MX MX2019010922A patent/MX2019010922A/es unknown
- 2018-03-16 WO PCT/US2018/022782 patent/WO2018170351A1/en unknown
- 2018-03-16 KR KR1020237037321A patent/KR20230155025A/ko active IP Right Grant
- 2018-03-16 KR KR1020197028728A patent/KR102597462B1/ko active IP Right Grant
- 2018-03-16 IL IL310464A patent/IL310464A/en unknown
- 2018-03-16 CN CN201880018431.7A patent/CN110799531B/zh active Active
- 2018-03-16 UY UY0001037635A patent/UY37635A/es unknown
- 2018-03-16 IL IL268700A patent/IL268700B1/en unknown
- 2018-03-16 BR BR112019019049A patent/BR112019019049A2/pt unknown
- 2018-03-16 MA MA047789A patent/MA47789A/fr unknown
- 2018-03-16 AU AU2018234709A patent/AU2018234709A1/en active Pending
- 2018-03-16 CN CN202310854848.XA patent/CN117209599A/zh active Pending
- 2018-03-16 BR BR122023021947-3A patent/BR122023021947A2/pt unknown
- 2018-03-16 SG SG11201907754RA patent/SG11201907754RA/en unknown
- 2018-03-16 US US15/923,011 patent/US10766953B2/en active Active
- 2018-03-16 JP JP2019549574A patent/JP7159185B2/ja active Active
- 2018-03-16 EA EA201992038A patent/EA201992038A1/ru unknown
- 2018-03-16 CA CA3055598A patent/CA3055598A1/en active Pending
-
2019
- 2019-08-28 PH PH12019501973A patent/PH12019501973A1/en unknown
- 2019-09-09 CL CL2019002566A patent/CL2019002566A1/es unknown
-
2020
- 2020-08-06 US US16/986,615 patent/US11365244B2/en active Active
-
2021
- 2021-02-26 ZA ZA2021/01318A patent/ZA202101318B/en unknown
-
2022
- 2022-05-18 US US17/747,785 patent/US20230047413A1/en active Pending
- 2022-10-12 JP JP2022164041A patent/JP2022191383A/ja not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022191383A5 (ja) | ||
| JP2022106952A5 (ja) | ||
| JP2024038003A5 (ja) | ||
| JP2022177090A5 (ja) | ||
| JP2023121798A5 (ja) | ||
| JP2018536393A5 (ja) | ||
| JP2023116770A5 (ja) | ||
| JP2023093753A5 (ja) | ||
| JP2020505017A5 (ja) | ||
| RU2012112829A (ru) | Анти-gitr-антитела | |
| JP2020511946A5 (ja) | ||
| JP2018535650A5 (ja) | ||
| JP2024026132A5 (ja) | ||
| JP2024024114A5 (ja) | ||
| JP2020505927A5 (ja) | ||
| JP2020537520A5 (ja) | ||
| JPWO2019173291A5 (ja) | ||
| JP2016520595A5 (ja) | ||
| JP2020522280A5 (ja) | ||
| AR123083A1 (es) | Proteínas que comprenden dominios de unión al antígeno hla-g y sus usos | |
| JP2013543384A5 (ja) | ||
| JPWO2019224711A5 (ja) | ||
| JP2020515277A5 (ja) | ||
| JP2019509714A5 (ja) | ||
| JPWO2019209995A5 (ja) |